Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.
Study Details
Study Description
Brief Summary
CDK13 related disorder is mainly characterised by developmental delay (DD) and intellectual disability (ID), ranging from mild to severe, and malformation syndrome.
The aims of this study are first to better delineate the clinical phenotype, as well as the neuropsychological profile, and the brain MRI characteristics; and, second, to study the epigenetic signatures in a cohort of individuals with CDK13 intragenic pathogenic variants. This work will conduct to a MD thesis of a clinical resident geneticist in France.
Physician that will participate will fill an Excel sheet regarding the clinical and neuropsychological assessment.
The investigators will be also happy to have either CD-ROM or a link to have access to the brain MRI data as well as a DNA sample with a minimum 0.5ug of peripheral blood genomic DNA. The investigators will gather the DNA in Montpellier genetic lab (Dr Mouna BARAT) and send the batch to the Dr Sadikovic' lab.
Between 2019 and 2020, The investigators have already recruited data from individuals with CDK13 pathogenic variants from France and several European genetic centres.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The investigators aim to better understand and delineate the genetic syndrome CDK13 This genetic disorder was described in Sepember 2016 in Nature Genetics (PMID 27479907).
Since this first publication of 6 individuals carrying the pathogenic mutation CDK13, 37 other individuals carrying a pathogenic mutation of CDK13 have been reported in the litterature The investigators are seeking to better define the phenotype of individuals with pathogenic variants of CDK13, to better understand intellectual functioning as well as the strengths and weaknesses of intellectual functioning by collecting standardized neuropsychological assessments already performed such as WPPSI/WISC and WAIS. For this purpose, The investigators will gather clinical and neuropsychological data already carried out in the context of care.
The investigators also aim to gather the cerebral MRI scans already performed in order to better delimit the cerebral anomalies observed in individuals and if the sequence is adapted, The investigators will perform VBM studies.
Finally, The investigators will attempt to identify an epigenetic signature in this genetic disease. To this end, The investigators will collect genomic DNA from peripheral blood already collected for genetic analysis and send an anonymized batch of samples to our collaborator, Dr. Bekim Sadicovik. Dr. Bekim Sadicovik and his team will compare the epigenetic DNA methylation-type markers with the corresponding sex and age controls. If specific probes are abnormally methylated in CDK13 individuals, this will determine a disease-specific epigenetic signature. The investigators will then be able to propose an epigenetic signature for individuals with uncharacterized CDK13 variations (class 3, VUS). This method will make it possible to define whether the variation is responsible for the disease or not without going through functional analysis steps that are difficult to implement routinely.
The expected benefits are a better understanding of CDK13 disease, keys to neuropsychological rehabilitation, a better understanding of human brain functions, the possibility of proposing an epigenetic signature for people in whom it is not possible to decide whether a variation in the CDK13 gene is pathological or not
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| CDK13 CDK13 intragenic pathogenic variant |
Genetic: Epigenetic signatures
Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
|
Outcome Measures
Primary Outcome Measures
- Evolution of clinical data [1 day]
Clinical data such as growth parameters, facial, neurological, ENT, eye, cardiac, etc.. features
- Neuropsychological test [1 day]
Neuropsychological test with total IQ and subscore data using WISC or WAIS test
Secondary Outcome Measures
- Evolution of genetic data [1 day]
Evolution of genetic data : Epigenetic signatures
Eligibility Criteria
Criteria
Inclusion criteria:
- CDK13 intragenic pathogenic SNV (Single Nucleotide Variant)
Exclusion criteria:
-
no pathogenic SNV in CDK13
-
no consent for the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UH Montpellier | Montpellier | France | 34295 |
Sponsors and Collaborators
- University Hospital, Montpellier
Investigators
- Principal Investigator: David GENEVIEVE, Department of Medical Genetics
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RECHMPL20_0279